KinetiSol Amorphic Dispersions

The relentless pursuit of novel therapeutic agents pushes the boundaries of the chemical space, resulting in an increasing number of poorly soluble drug candidates. Drug absorption hinges on solubility within the digestive tract, making this trend a significant hurdle for formulators. In response to this growing challenge, AustinPx has been developing KinetiSol Technology since 2007.

KinetiSol is a solvent-free, fusion-based process that leverages frictional and shear forces to rapidly convert crystalline drugs and polymers into amorphous solid dispersions (ASDs). This innovative approach offers a robust solution for enhancing the bioavailability of poorly soluble drugs across various development stages. The technology's efficacy has been demonstrated with notoriously insoluble molecules like deferasirox, abiraterone, tetrabenazine, and vemurafenib, highlighting its broad applicability.